Electromed, Inc. Hits New 52-Week High of $39.35, Up 468.6%

Electromed, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 39.35 on May 28, 2026. This achievement marks a remarkable performance over the past year, with the stock soaring 468.6%, significantly outpacing the S&P 500's growth of 28.45% during the same period. The company's market capitalization stands at USD 197 million, reflecting its position within the microcap category. Electromed's price-to-earnings (P/E) ratio is currently at 22.00, indicating a valuation that is in line with its growth trajectory. Additionally, the company maintains a return on equity of 20.11%, showcasing its efficiency in generating profits from shareholders' equity. With a 52-week low of USD 17.73, the stock's upward movement highlights a strong recovery and growth trend. Electromed's financial metrics, including a price-to-book ratio of 4.33 and a debt-to-equity ratio of -0.30, further illustrate its financial health and stability in the competitive biotechnology landscape.